Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma

BCMA targeting chimeric antigen receptor (CAR) T cell therapy has shown deep and durable responses in multiple myeloma. However, relapse following therapy is frequently observed, and mechanisms of resistance remain ill-defined. Here, we perform single cell genomic characterization of longitudinal sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Samur, Mehmet Kemal, Fulciniti, Mariateresa, Aktas Samur, Anil, Bazarbachi, Abdul Hamid, Tai, Yu-Tzu, Prabhala, Rao, Alonso, Alejandro, Sperling, Adam S., Campbell, Timothy, Petrocca, Fabio, Hege, Kristen, Kaiser, Shari, Loiseau, Hervé Avet, Anderson, Kenneth C., Munshi, Nikhil C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870932/
https://www.ncbi.nlm.nih.gov/pubmed/33558511
http://dx.doi.org/10.1038/s41467-021-21177-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870932/
https://www.ncbi.nlm.nih.gov/pubmed/33558511
http://dx.doi.org/10.1038/s41467-021-21177-5

Ejemplares similares